Clinical outcomes of total femoral replacement. First Latin American experience.

INTRODUCTION: The femur is frequently affected by primary and metastatic bone tumors. In cases with substantial bone loss, Total Femur Replacement (TFR) remains the only viable limb preservation option. This study investigates the clinical outcomes of TFR patients in a Latin American setting, with a minimum 3-year follow-up. METHODS: Retrospective review identifying cases of TFR at a single center from 2009 to 2020. Patients who had TFR either due to oncological indications or complications arising from oncology-related surgeries were included. Data on the indications for surgery and post-operative complications were recorded. To assess functional status, the Musculoskeletal Tumor Society (MSTS) score and the Toronto Extremity Salvage Score (TESS) were used. RESULTS: Fourteen patients met the inclusion criteria. Diagnoses included eight osteosarcomas, four chondrosarcomas, one Ewing sarcoma, and one giant cell tumor. Ten patients had undergone prior surgeries. Indication for TFR was a complication of a previous surgery in 78.6 % of cases. Post-TFR complications were experienced by 35.7 % of patients, requiring further surgeries. At the 3-year mark, average MSTS and TESS scores were 67.4 % and 70.8 %, respectively. CONCLUSION: Total femur replacement serves as a valuable limb salvage solution for patients with significant femoral defects in oncological scenarios, however, there is a significant risk of complications. Given its potential benefits, it is essential for developing countries to consider incorporating TFR into their healthcare systems.

Comparison between different prognostic models to be used for metastatic bone disease on appendicular skeleton in a Chilean population.

PURPOSE: Several preoperation prognosis models used on the treatment of metastatic bone disease on appendicular skeleton have been devised. The purpose of this study was to compare the performance of different survival prognostic models on patients with metastatic bone disease in long bones in a Chilean population. METHODS: This is a multicentric retrospective study. We retrospectively reviewed the medical records of 136 patients who were confirmed with metastatic bone disease of the appendicular skeleton and who were treated surgically from 2016 to 2019. The minimum follow-up time was 12 months. All patients were assessed using four appendicular metastatic bone disease scoring systems. A preoperative predicted survival time for all 136 patients was retrospectively calculated making use of the revised Katagiri, PathFx, Optimodel and IOR score model. RESULTS: The PathFx model demonstrated an accuracy at predicting 3 (area under the curve [AUC] = 0.61) and 6-month (AUC = 0.65) survival time after surgical management. IOR score model demonstrated an accuracy at predicting 12-month survival time (AUC = 0.64). The survival rate reached the 44% in a year. The median survival time to death or last follow-up time was 14.9 months (SD ± 15). CONCLUSION: PathFx score model demonstrated the highest accuracy at predicting a survival time of 3 and 6 months. IOR score model was the most accurate measure at predicting a survival time of 12-months. To our knowledge, this is the first study reporting a comparative analysis of metastatic bone disease with predicting models in a country located in Latin America. PathFx's and IOR score models are the ones to be used in the Chilean population as the predictive models in metastatic bone disease of the appendicular skeleton.

Metástasis óseas: II parte / Bone metastases: II part

En este artículo se da a conocer la importancia que tiene el diagnóstico y el tratamiento de las metástasis óseas. Se analiza en forma retrospectiva el Registro de Lesiones Músculo-esqueléticas del Instituto Traumatológico en el período comprendido entre 1987 y 1995. Las conclusiones, resultados y sugerencias que se presentan en este trabajo corresponden al análisis de 250 pacientes portadores de metástasis óseas diagnosticadas y tratadas en el Instituto Traumatológico; todos los casos fueron estudiados con un mismo protocolo y su diagnóstico definitivo fue apoyado por el estudio citológico y/o histológico (biopsia). Se describe la técnica para obtener la biopsia. Su localización anatómica más frecuente fue el fémur proximal (36 por ciento). Se describe el protocolo general de tratamiento cirugía y posterior radioterapia. Se analizan los distintos esquemas terapéuticos según las localizaciones de las lesiones óseas, así como las comparaciones de los pacientes diagnosticados y no tratados, respecto a los tratados. Concluimos que siempre se debe realizar biopsia del tumor y tratar a los pacientes de acuerdo a un protocolo preestablecido

Metástasis oseas / Bone metastases

Se describe la importancia que tiene en el estudio de las enfermedades neoplásicas el diagnóstico de las metástasis óseas. En el período comprendido entre 1987 y 1996 se revisó y se analizó en forma retrospectiva, el Registro de Lesiones Musculoesqueléticos del Instituto Traumatológico, describiendo a las metástasis óseas como una lesión tumoral ósea secundaria. Se enfatiza que para el correcto diagnóstico de metástasis óseas se requiere de la triada que considera la clínica, radiología e histopatología. Se analizan 250 casos de metástasis óseas, comprobándose que no hay diferencias significativas respecto al sexo y que la edad de aparición más frecuente es en la década de los 51-60 años (27 por ciento). La forma clínica más habitual de presentación fue el dolor; 82 por ciento de los casos. Su localización anatómica más frecuente se ubica en el fémur proximal (36 por ciento). Los cánceres primarios que más metástasis óseas provocaron fueron: mama 25,2 por ciento;próstata 20,2 por ciento; pulmón 18,2 por ciento y riñón 15 por ciento. Finalmente, se hace referencia a las metásasis óseas y la detección previa del cáncer que les dio origen